FDA Approves 9-Valent HPV Vaccine for Males 16-26

The FDA approved use of the 9vHPV vaccine for males aged 16-26 years, extending the previous indication that was for females aged 9-26 years and males aged 9-15 years. The current Advisory Committee on Immunization Practices’ (ACIP) 9vHPV vaccination recommendation includes males through age 21 and through age 26 years for men who have sex with men and for those immunocompromised, including with HIV infection. With this FDA approval, the ACIP recommendation for males aged 16-26 is no longer “off label.” Read the approval letter here.

About Alyssa Kitlas

Alyssa Kitlas serves as a Program Analyst on NACCHO's HIV, STI, and Viral Hepatitis team. Her work includes projects on HIV, STI, and Viral Hepatitis prevention and care. Twitter: @AlyssaKitlas

Leave a Reply

Your email address will not be published. Required fields are marked *